Key Points
- Insider sale: Erick Wayne Devinney sold 5,221 shares at an average price of $32.84 for a total of $171,457.64, trimming his stake by about 1.95% to 262,781 shares.
- Stock performance and fundamentals: AXGN opened at $30.94 and was trading down ~5.5%; the company has a 1‑year range of $9.22–$36.00, a $1.61B market cap and a negative PE (-91), and it missed quarterly EPS by $0.01 with a negative net margin of 6.97%.
- Analyst sentiment: Nine analysts rate AxoGen a Buy and one a Sell, giving a consensus rating of "Moderate Buy" with an average price target of $39.38.
AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) insider Erick Wayne Devinney sold 5,221 shares of AxoGen stock in a transaction on Monday, March 16th. The shares were sold at an average price of $32.84, for a total value of $171,457.64. Following the completion of the sale, the insider owned 262,781 shares in the company, valued at $8,629,728.04. This represents a 1.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
AxoGen Trading Down 5.5%
Shares of AXGN stock opened at $30.94 on Thursday. AxoGen, Inc. has a 1-year low of $9.22 and a 1-year high of $36.00. The firm has a market cap of $1.61 billion, a PE ratio of -91.00 and a beta of 0.98. The company has a 50-day moving average of $32.67 and a two-hundred day moving average of $26.53. The company has a debt-to-equity ratio of 0.51, a current ratio of 5.11 and a quick ratio of 3.31.
AxoGen (NASDAQ:AXGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 24th. The medical equipment provider reported $0.07 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.01). The company had revenue of $59.90 million during the quarter, compared to analyst estimates of $59.90 million. AxoGen had a negative return on equity of 13.44% and a negative net margin of 6.97%. On average, analysts predict that AxoGen, Inc. will post -0.29 EPS for the current year.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on AXGN shares. Weiss Ratings reiterated a "sell (e+)" rating on shares of AxoGen in a report on Monday, December 29th. HC Wainwright lifted their target price on AxoGen from $26.00 to $39.00 and gave the company a "buy" rating in a research report on Friday, December 5th. Jefferies Financial Group boosted their price target on shares of AxoGen from $29.00 to $36.00 and gave the stock a "buy" rating in a research note on Thursday, December 4th. Mizuho initiated coverage on shares of AxoGen in a research report on Monday, December 1st. They set an "outperform" rating and a $40.00 price target on the stock. Finally, Citizens Jmp raised their price objective on shares of AxoGen from $34.00 to $42.00 and gave the company a "market outperform" rating in a research note on Tuesday, February 24th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $39.38.
View Our Latest Stock Report on AXGN
Hedge Funds Weigh In On AxoGen
Institutional investors and hedge funds have recently modified their holdings of the company. Commonwealth Equity Services LLC raised its stake in AxoGen by 1.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 21,473 shares of the medical equipment provider's stock valued at $703,000 after buying an additional 371 shares in the last quarter. Arax Advisory Partners boosted its position in shares of AxoGen by 362.4% during the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider's stock worth $34,000 after acquiring an additional 819 shares in the last quarter. Brooklyn Investment Group increased its holdings in shares of AxoGen by 4.2% in the 4th quarter. Brooklyn Investment Group now owns 20,568 shares of the medical equipment provider's stock valued at $688,000 after acquiring an additional 823 shares during the last quarter. MCF Advisors LLC acquired a new stake in shares of AxoGen during the 4th quarter worth about $30,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of AxoGen by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider's stock worth $466,000 after acquiring an additional 1,057 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company's stock.
AxoGen Company Profile
(
Get Free Report)
AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen's offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.
The company's core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
